Back to Search
Start Over
Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis.
- Source :
-
Journal of Oncology . 10/20/2022, p1-9. 9p. - Publication Year :
- 2022
-
Abstract
- Purpose. To compare the efficacy of EGFR-TKIs combined with antiangiogenic agents between non-small cell lung cancer patients with exon 19 deletion and patients with exon 21 Leu858 Arg mutation. Methods. Electronic databases (PubMed, Embase, and the Cochrane Central Register of Controlled Trials) were systematically searched for studies published until March 2022. Randomized control trials comparing the survival of EGFR-TKIs plus antiangiogenic agents with EGFR-TKI were extracted. The primary endpoint was progression-free survival (PFS). Results. Five randomized control trials involving 1533 patients were as follows: 818 patients had exon 19 deletion, and 715 patients with exon 21 Leu858 Arg mutation. The methodological quality of the 5 randomized control trials was high. EGFR-TKIs plus antiangiogenic agents improved PFS in patients with exon 19 deletion (hazard ratio [HR] = 0.62, 95% confidence interval [CI]: 0.51–0.75) and exon 21 Leu858 Arg mutation (HR = 0.61, 95% CI: 0.50–0.75). PFS did not differ between the exon 19 deletion and exon 21 Leu858 Arg mutation groups (Z = 0.07, P = 0.94). Conclusions. PFS was comparable between patients receiving EGFR-TKIs combined with antiangiogenic agents with exon 19 deletion and those with exon 21 Leu858 Arg mutation. [ABSTRACT FROM AUTHOR]
- Subjects :
- *LUNG cancer prognosis
*DRUG efficacy
*LUNG cancer
*ONLINE information services
*MEDICAL databases
*COMBINATION drug therapy
*GENETIC mutation
*NEOVASCULARIZATION inhibitors
*META-analysis
*MEDICAL information storage & retrieval systems
*CONFIDENCE intervals
*EPIDERMAL growth factor receptors
*SYSTEMATIC reviews
*PROTEIN-tyrosine kinase inhibitors
*TREATMENT effectiveness
*CANCER patients
*DESCRIPTIVE statistics
*MEDLINE
*PROGRESSION-free survival
*EVALUATION
Subjects
Details
- Language :
- English
- ISSN :
- 16878450
- Database :
- Academic Search Index
- Journal :
- Journal of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 159798501
- Full Text :
- https://doi.org/10.1155/2022/9399797